Journal
DRUGS
Volume 80, Issue 11, Pages 1119-1124Publisher
ADIS INT LTD
DOI: 10.1007/s40265-020-01343-7
Keywords
-
Categories
Ask authors/readers for more resources
Selpercatinib (RETEVMO (TM)) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment ofRETfusion-positive non-small-cell lung cancer,RETfusion-positive thyroid cancer andRET-mutant medullary thyroid cancer. This article summarizes the milestones in the development of selpercatinib leading to this first approval.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available